Bicycle therapeutics announces publication of article highlighting preclinical data from bt7480 program in the journal for immunotherapy of cancer

Cambridge, england, & boston--(business wire)--bicycle therapeutics plc (nasdaq: bcyc), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (bicycle®) technology, today announced that an article highlighting preclinical data from bt7480, a tumor-targeted immune cell agonist (tica) targeting nectin-4 and agonizing cd137 (4-1bb), was published in the journal for immunotherapy of cancer (jitc). the article, titled “bt7480, a n
BCYC Ratings Summary
BCYC Quant Ranking